Welcome to our dedicated page for Tourmaline Bio SEC filings (Ticker: TRML), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive for Tourmaline Bio, Inc. (former Nasdaq symbol TRML) provides a detailed regulatory record of the company’s operations as a late-stage clinical biotechnology issuer and its subsequent acquisition by Novartis AG. These documents include current reports on Form 8-K, periodic reports, and other materials that outline both clinical and corporate milestones.
For investors and researchers, Form 8-K filings are particularly important. One Form 8-K dated September 9, 2025 describes the entry into an Agreement and Plan of Merger among Tourmaline, Novartis, and a Novartis subsidiary, including the terms of a cash tender offer for all outstanding shares of Tourmaline common stock. A later Form 8-K dated October 28, 2025 reports completion of the tender offer, the subsequent merger under Delaware law, and the resulting change in control, with Tourmaline becoming an indirect wholly owned subsidiary of Novartis.
The October 28, 2025 Form 8-K also discusses the treatment of Tourmaline common stock and equity awards in the merger and notes that, in connection with the transaction, the company requested suspension and delisting of its shares from the Nasdaq Global Select Market and the filing of a Form 25. The same filing indicates that Tourmaline intended to file a Form 15 to deregister its common stock and suspend its reporting obligations under the Exchange Act.
Earlier filings and exhibits referenced in these 8-Ks provide additional context on the merger agreement, interim operating covenants, termination provisions, and any applicable termination fees. Other 8-Ks, such as the August 13, 2025 report, furnish earnings press releases and business highlights, including updates on the Phase 2 TRANQUILITY trial of pacibekitug and the company’s financial condition.
On this page, Stock Titan surfaces Tourmaline’s historical SEC filings and pairs them with AI-generated summaries to help readers quickly understand key points, such as merger terms, delisting steps, and clinical and financial disclosures. Users can review 10-Ks, 10-Qs, 8-Ks, and related exhibits where available, while AI highlights material events, changes in control, and other items that shaped the trajectory of TRML as a public company before it became part of Novartis.
QVT Financial LP reported beneficial ownership of 2,154,653 shares of Tourmaline Bio, Inc. common stock, representing 8.39% of the class. The filing states these shares are held with sole voting and dispositive power and were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control. The document identifies QVT Financial LP as a Delaware entity and provides its address as 888 Seventh Avenue, 43rd Floor, New York, NY 10106. The statement was signed by an authorized signatory on behalf of QVT Financial LP.
Avoro Capital Advisors LLC and Behzad Aghazadeh reported beneficial ownership of 2,555,555 shares of Tourmaline Bio, Inc. common stock, equal to 9.95% of the class. The percentage is calculated using an aggregate of 25,688,479 shares outstanding as disclosed by the company for the quarter ended March 31, 2025.
The filing identifies Avoro as the investment adviser holding the shares on behalf of Avoro Life Sciences Fund LLC and names Dr. Aghazadeh as the portfolio manager and controlling person. The reporting persons state they have sole voting and dispositive power over the reported shares and certify the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control.
Tourmaline Bio, Inc. (TRML) reported unaudited results for the quarter ended June 30, 2025 showing continued investment in clinical development of pacibekitug and a solid liquidity position. The company held $256.4 million in cash, cash equivalents and investments and reported a net loss of $46.1 million for the six months ended June 30, 2025, widening from $30.8 million a year earlier due to higher research and development spending.
Research and development expenses rose to $39.9 million for the six-month period, driven by higher clinical trial and toxicology costs as Tourmaline advanced the TRANQUILITY and spiriTED programs. The company disclosed positive Phase 2 TRANQUILITY topline results showing rapid, deep and durable reductions in hs-CRP with quarterly dosing and reported comparable adverse event rates to placebo through the data extract date. Management expects existing funds to support operations into the second half of 2027 and plans further development including a potential Phase 3 cardiovascular outcomes trial and a Phase 2 proof-of-concept study in abdominal aortic aneurysm.
Tourmaline Bio, Inc. furnished a Current Report on Form 8-K stating it issued a press release announcing business highlights and financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The company states this information is being furnished, not filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless expressly stated.
The 8-K contains no numerical financial data or operational detail itself; readers must consult Exhibit 99.1 for the actual figures and narrative. The registrant's common stock trades under TRML on the Nasdaq Global Select Market and no other material transactions or financial tables are included in this filing.